5-FUMCL: A selective and low-hepatotoxicity NLRP3 inflammasome inhibitor for treating inflammatory diseases
Journal of Pharmaceutical Analysis · 2026-10 · 101821
DOI: 10.1016/j.jpha.2026.101821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-10. Verfasst von Xuyun Liu und 13 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The activation of nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3) inflammasome plays a pivotal role in the pathogenesis of numerous inflammatory conditions. Despite significant advances in the development of its inhibitors, their clinical translation remains challenging due to efficacy and hepatotoxicity concerns. We previously synthesized a new molecule, 5-FUMCL, a derivative of micheliolide, which demonstrated robust anti-inflammatory properties. Here, we report that 5-FUMCL inhibits the assembly of the NLRP3 inflammasome by interacting with the pyrin domain (PYD) of NLRP3, with W68 and P92 being critical residues for this interaction. Consequently, 5-FUMCL exhibits potent anti-inflammatory effects across various mouse models of inflammatory conditions, including peritonitis, arthritis, endotoxic shock, and diabetes, with its efficacy nullified in Nlrp3 knockout mice. Compared to MCC950, a well-established preclinical NLRP3 inhibitor, 5-FUMCL shows similar anti-inflammatory effects while exhibiting a superior hepatic safety profile upon both acute and chronic treatments. Furthermore, 5-FUMCL has proven effective in both a porcine model of endotoxic shock and a human macrophage model of NLRP3 inflammasome activation. These findings highlight 5-FUMCL as a promising inhibitor of the NLRP3 inflammasome, distinguished by its high selectivity and low toxicity profile. This positions 5-FUMCL as a potential therapeutic agent for a wide range of inflammatory disorders in the clinic.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, X., Wen, Y., Liao, X., Wang, S., Yan, Y., Li, M., Yu, S., Zhang, Z., Li, J., Liu, J., Gao, F., Qin, X., Qin, X., & Zhang, X. (2026). 5-FUMCL: A selective and low-hepatotoxicity NLRP3 inflammasome inhibitor for treating inflammatory diseases. Journal of Pharmaceutical Analysis, 101821. https://doi.org/10.1016/j.jpha.2026.101821
Vancouver
Liu X, Wen Y, Liao X, Wang S, Yan Y, Li M, et al. 5-FUMCL: A selective and low-hepatotoxicity NLRP3 inflammasome inhibitor for treating inflammatory diseases. Journal of Pharmaceutical Analysis. 2026:101821. doi:10.1016/j.jpha.2026.101821
BibTeX
@article{Liu2026,
author = {Liu, Xuyun and Wen, Ying and Liao, Xinyu and Wang, Shuang and Yan, Yizhen and Li, Min and Yu, Sen and Zhang, Ziang and Li, Jia and Liu, Jiankang and Gao, Feng and Qin, Xinghua and Qin, Xiangyang and Zhang, Xing},
title = {5-FUMCL: A selective and low-hepatotoxicity NLRP3 inflammasome inhibitor for treating inflammatory diseases},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
pages = {101821},
doi = {10.1016/j.jpha.2026.101821}
}
EUVIMED